Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (NCT04482309) | AstraZeneca | 2020-08-18 |
Track Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer automatically
Every clearance here is in the API, with alerts when new ones post.